GLP-1 Agonists Expose Hidden Cardiometabolic Pathways in Obesity-Autoimmune Overlap

The OneFlorida+ observational analysis of 26,000 adults reveals GLP-1 receptor agonists cut all-cause mortality by 44 percent and venous thromboembolism by 17 percent in patients with obesity plus autoimmune disease, yet its retrospective design leaves residual confounding unaddressed and lacks randomization. This real-world evidence builds on the SELECT trial's 20 percent MACE reduction in obesity without diabetes while hinting at anti-inflammatory effects that extend past weight loss, an angle mainstream coverage routinely underplays. Earlier mechanistic work in rheumatoid arthritis cohorts shows GLP-1 signaling dampens IL-6 and TNF-alpha, patterns that align with the 31 percent pulmonary embolism drop observed here. No conflicts were declared by Sheer et al., though industry ties in the broader GLP-1 literature warrant scrutiny. The modest 13 percent stroke signal and nonsignificant myocardial infarction trend suggest benefits concentrate on thrombo-inflammatory rather than purely atherosclerotic routes, a distinction prior studies in isolated autoimmune populations missed.